Results 331 to 340 of about 256,425 (387)

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Efficacy and Safety of Drug and Device Strategies for Stroke Prevention in Atrial Fibrillation After Intracranial Hemorrhage: A Bayesian Network Meta-Analysis. [PDF]

J Cardiovasc Dev Dis
Qi F, Yang Y, Wang L, Weng S, Wu Q, Liu Y, Hu Z, Chen L, Wang Y.   +8 more
europepmc   +1 more source

Prior Dual Antiplatelet Therapy and Mortality After Intracerebral Hemorrhage: A Danish Nationwide Cohort Study. [PDF]

J Am Heart Assoc
Ovesen C, García Rodríguez LA, Hallas J, Storm C, Hald SM, Möller S, Selim M, Gaist D.   +7 more
europepmc   +1 more source

Antiplatelet therapy.

Nihon Naika Gakkai Zasshi, 1999
openaire   +2 more sources

Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis. [PDF]

Front Pharmacol
Mohammed S, Ali Z, Mohammed N, El-Menyar A, Al Suwaidi J, Al-Hail M, Al-Muftah W, Abdel-Latif R, Sim MS.   +8 more
europepmc   +1 more source

Extending Dual Antiplatelet Therapy Beyond 3 Months in Acute Ischemic Stroke Due to Large-Artery Atherosclerosis. [PDF]

J Am Heart Assoc
Lee M, Oh MS, Yu KH, Lee BC, Kim BJ, Kim JY, Kang J, Kim DY, Park JM, Kang K, Park TH, Lee JY, Lee KB, Hong KS, Park HK, Cho YJ, Eog-Kim D, Lee SJ, Kim JG, Lee J, Cha JK, Kim DH, Kim JT, Choi KH, Choi JC, Sohn SI, Hong JH, Lee SH, Kim C, Shin DI, Yum KS, Lee J, Lee JS, Gorelick PB, Bae HJ, CRCS‐K Investigators *.   +35 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

Circulation, 2023
Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or ischemic events in patients with coronary artery disease treated with percutaneous coronary intervention and those treated medically for an acute coronary syndrome ...
D. Capodanno, R. Mehran, M. Krucoff, U. Baber, Deepak L. Bhatt, P. Capranzano, J. Collet, T. Cuisset, G. De Luca, L. De Luca, A. Farb, Francesco Franchi, C. Gibson, J. Hahn, M. Hong, S. James, A. Kastrati, T. Kimura, P. Lemos, R. Lopes, Adrian Magee, R. Matsumura, S. Mochizuki, M. O’Donoghue, N. Pereira, S. Rao, F. Rollini, Y. Shirai, D. Sibbing, P. Smits, P. Steg, R. Storey, Jurrien ten Berg, M. Valgimigli, P. Vranckx, Hirotoshi Watanabe, S. Windecker, P. Serruys, R. Yeh, M. Morice, D. Angiolillo   +40 more
semanticscholar   +1 more source